Literature DB >> 23511192

Therapy monitoring of magnetic resonance-guided radiofrequency ablation using T1- and T2-weighted sequences at 1.5 T: reliability of estimated ablation zones.

Hansjörg Rempp1, Johannes Unterberg, Rüdiger Hoffmann, Philippe L Pereira, Fritz Schick, Claus D Claussen, Stephan Clasen.   

Abstract

PURPOSE: The aim of this study was to compare the size and shape of the indicated ablation zone using magnetic resonance (MR) imaging with different contrast weightings after MR-guided radiofrequency ablation (RFA) at 1.5 T.
MATERIALS AND METHODS: Magnetic resonance images of 50 patients treated for hepatic malignancies using MR-guided RFA were retrospectively evaluated. Areas indicating ablation zones in contrast-enhanced images were compared with nonenhanced T1- and T2-weighted images acquired after the intervention and 1 and 7 months after therapy. Corresponding slices were selected and registered to each other. Regions indicating ablation zones were segmented and compared. Areas in cm, positive predictive value, and sensitivity of native T1- and T2-weighted images were calculated with regard to their accordance with the contrast-enhanced images.
RESULTS: Directly after the intervention, the ratios between the areas of the ablation zone in the contrast-enhanced and the tested sequences were 1.02 ± 0.12 in the T1-weighted images and 2.03 ± 0.78 in the T2-weighted images. Sensitivity (portion of the coagulation zone that was correctly detected based on the tested sequences) was 0.88 ± 0.08 using the T1-weighted and 0.54 ± 0.20 using the T2-weighted images. The positive predictive values were 0.89 ± 0.06 (T1 weighted) and 0.93 ± 0.06 (T2 weighted). One month after therapy, the ratios between the areas in the contrast-enhanced and the tested sequences were 1.02 ± 0.12 in the T1-weighted images and 1.04 ± 0.25 in the T2-weighted images. Seven months after therapy, the ratios were 1.04 ± 0.16 in the T1-weighted and 1.18 ± 0.22 in the T2-weighted images.
CONCLUSION: In examinations performed directly after the intervention, the T2-weighted images tend to underestimate the ablation zone, whereas T1-weighted images clearly better reflect the ablation zone. T1-weighted images therefore seem more adequate for repetitive monitoring of MR-guided RFA at 1.5 T.

Entities:  

Mesh:

Year:  2013        PMID: 23511192     DOI: 10.1097/RLI.0b013e318280b007

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  3 in total

1.  Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update.

Authors:  Muneeb Ahmed; Luigi Solbiati; Christopher L Brace; David J Breen; Matthew R Callstrom; J William Charboneau; Min-Hua Chen; Byung Ihn Choi; Thierry de Baère; Gerald D Dodd; Damian E Dupuy; Debra A Gervais; David Gianfelice; Alice R Gillams; Fred T Lee; Edward Leen; Riccardo Lencioni; Peter J Littrup; Tito Livraghi; David S Lu; John P McGahan; Maria Franca Meloni; Boris Nikolic; Philippe L Pereira; Ping Liang; Hyunchul Rhim; Steven C Rose; Riad Salem; Constantinos T Sofocleous; Stephen B Solomon; Michael C Soulen; Masatoshi Tanaka; Thomas J Vogl; Bradford J Wood; S Nahum Goldberg
Journal:  J Vasc Interv Radiol       Date:  2014-10-23       Impact factor: 3.464

2.  Single-centre survival analysis over 10 years after MR-guided radiofrequency ablation of liver metastases from different tumour entities.

Authors:  Susann-Cathrin Olthof; Daniel Wessling; Moritz T Winkelmann; Hansjörg Rempp; Konstantin Nikolaou; Rüdiger Hoffmann; Stephan Clasen
Journal:  Insights Imaging       Date:  2022-03-21

3.  MRI-guided percutaneous thermoablation in combination with hepatic resection as parenchyma-sparing approach in patients with primary and secondary hepatic malignancies: single center long-term experience.

Authors:  Moritz T Winkelmann; Rami Archid; Georg Gohla; Gerald Hefferman; Jens Kübler; Jakob Weiss; Stephan Clasen; Konstantin Nikolaou; Silvio Nadalin; Rüdiger Hoffmann
Journal:  Cancer Imaging       Date:  2020-05-27       Impact factor: 3.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.